Neumora Therapeutics, Inc. Forecasted to Earn Q3 2024 Earnings of ($0.37) Per Share (NASDAQ:NMRA)

Neumora Therapeutics, Inc. (NASDAQ:NMRA) – Investment analysts at William Blair lowered their Q3 2024 earnings estimates for shares of Neumora Therapeutics in a note issued to investors on Tuesday, May 7th. William Blair analyst M. Minter now forecasts that the company will post earnings per share of ($0.37) for the quarter, down from their previous estimate of ($0.36). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Neumora Therapeutics’ current full-year earnings is ($1.48) per share. William Blair also issued estimates for Neumora Therapeutics’ FY2024 earnings at ($1.43) EPS, Q1 2025 earnings at ($0.38) EPS, Q2 2025 earnings at ($0.39) EPS, Q3 2025 earnings at ($0.39) EPS, Q4 2025 earnings at ($0.40) EPS and FY2025 earnings at ($1.57) EPS.

Neumora Therapeutics (NASDAQ:NMRA) last released its earnings results on Tuesday, May 7th. The company reported ($0.34) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.34).

Several other brokerages have also recently commented on NMRA. JPMorgan Chase & Co. raised their price objective on shares of Neumora Therapeutics from $20.00 to $22.00 and gave the company an “overweight” rating in a research note on Monday, March 18th. Royal Bank of Canada reissued an “outperform” rating and set a $31.00 price target on shares of Neumora Therapeutics in a research note on Thursday, March 28th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $22.57.

Neumora Therapeutics Price Performance

Neumora Therapeutics stock opened at $9.77 on Friday. Neumora Therapeutics has a one year low of $8.82 and a one year high of $21.00. The business has a fifty day moving average of $13.16 and a two-hundred day moving average of $14.04.

Hedge Funds Weigh In On Neumora Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NMRA. Amalgamated Bank purchased a new position in shares of Neumora Therapeutics during the 4th quarter worth approximately $29,000. Tower Research Capital LLC TRC acquired a new stake in Neumora Therapeutics during the 4th quarter valued at $44,000. Strs Ohio purchased a new position in Neumora Therapeutics during the fourth quarter worth $54,000. SG Americas Securities LLC purchased a new stake in shares of Neumora Therapeutics in the fourth quarter valued at $108,000. Finally, New York State Common Retirement Fund acquired a new stake in shares of Neumora Therapeutics during the fourth quarter valued at $118,000. Institutional investors and hedge funds own 47.65% of the company’s stock.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.